tnp

TNP (IP3K Inhibitor) is a cell-permeable inhibitor of IP6K1 and IP3K, with IC 50 values of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP binds to the ATP-binding sites of both enzymes [1].

TNP-470 is a methionine aminopeptidase-2 inhibitor and an angiogenesis inhibitor.

Tnp 351 is a novel antifolate drug being assessed for chemotherapy of lung cancer.

P2X receptor antagonist

PALATINOSE (TNP-470) is a natural occurring disaccharide composed of alpha-1,6-linked glucose and fructose。 PALATINOSE has a beneficial effect on liver metabolic functions and might therefore be a good substitute for sucrose as a sweetener.

CBR-2092 is a DNA-directed RNA polymerase and DNA topoisomerase inhibitor. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance.

BTNPO is a unimolecular two-photon fluorescent probe that is highly sensitive and selective for detecting peroxynitrite (ONOO^-). It exhibits excellent photostability and cell permeability, making it suitable for biological imaging applications. In the presence of peroxynitrite, BTNPO undergoes a significant fluorescence enhancement, which allows for real-time monitoring of cellular events.

TTNPB (Ro 13-7410,AGN-191183), a potent RAR agonist, inhibits binding of [3H]tRA of human RARα (IC50: 5.1 nM), β (IC50: 4.5 nM), and γ (IC50: 9.3 nM), respectively.

Fumagillol is a direct precursor of the potent angiogenesis inhibitors [TNP-470] and (fumagillin).

A-849519 is a reversible inhibitor of MetAP2 that has demonstrated anti-angiogenesis and anticancer activity in a number of in vitro and in vivo models. In this study, we evaluated the anticancer activity of A-849519 in a modified Dunning model of androgen-independent prostate cancer and compared its efficacy with TNP-470, an established MetAP2 inhibitor.

Rifasutenizol (TNP-2198) is an orally bioavailable, dual-targeted antibacterial agent with potent effectiveness against both microaerophilic and anaerobic bacterial pathogens [1].